Intellectual property « Science and Enterprise

New Company to Develop Synthetic Antibody Therapies

By Alan, on November 15th, 2021%

A new business is underway to develop and commercialize treatments for Covid-19 and other diseases based on synthetic antibody proteins. . . . → Read More: New Company to Develop Synthetic Antibody Therapies

Crispr Licensed for Eye Disease Gene Therapies

By Alan, on October 13th, 2021%

A developer of inherited eye disease therapies is acquiring rights to the gene editing technology Crispr for treatments that work inside the eyes. . . . → Read More: Crispr Licensed for Eye Disease Gene Therapies

Delivery Tech Licensed for CBD Epilepsy Nasal Spray

By Alan, on September 20th, 2021%

A company is developing a nasal spray for epilepsy symptoms with a cannabis extract delivered in nanoscale polymer particles to the brain. . . . → Read More: Delivery Tech Licensed for CBD Epilepsy Nasal Spray

Biotechs Partner on Agitation Detection Technology

By Alan, on September 2nd, 2021%

Two developers of treatments and tools for neurological diseases are developing a system for early detection of agitation, a symptom of psychiatric disorders. . . . → Read More: Biotechs Partner on Agitation Detection Technology

New Company Forms to Ease Scientific Data Operations

By Alan, on August 16th, 2021%

A new company spun off from Harvard University aims to simplify data analysis, management, and collaboration for life science researchers. . . . → Read More: New Company Forms to Ease Scientific Data Operations

Pharma Gains Synthetic DNA for Rare Diseases in $1B+ Deal

By Alan, on August 2nd, 2021%

A French biopharmaceutical company is gaining access to a technology using synthetic nucleic acids to treat rare genetic neurological diseases. . . . → Read More: Pharma Gains Synthetic DNA for Rare Diseases in $1B+ Deal

Pharma, Biotech Partner on Off-the-Shelf Cell Therapies

By Alan, on July 30th, 2021%

A biotechnology enterprise is teaming with a pharmaceutical company to develop off-the-shelf therapies for malfunctioning mitochondria, energy centers of cells. . . . → Read More: Pharma, Biotech Partner on Off-the-Shelf Cell Therapies

GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal

By Alan, on July 2nd, 2021%

GlaxoSmithKline and biotechnology company Alector Inc. agreed to co-develop two synthetic antibodies for treating neurodegenerative disorders. . . . → Read More: GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal

Microbiome Drug Candidate Licensed in $525M Deal

By Alan, on July 1st, 2021%

A therapy designed to regenerate healthy gut microbes for treating dangerous intestinal infections is licensed for commercialization to Nestlé Health Science. . . . → Read More: Microbiome Drug Candidate Licensed in $525M Deal

Patent Awarded for Safer Cancer Drug Delivery

By Alan, on June 18th, 2021%

A pharmaceutical R&D company is receiving a patent for its process that encapsulates and better targets chemotherapy drugs for cancer patients. . . . → Read More: Patent Awarded for Safer Cancer Drug Delivery

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise